Accueil
Détail de l'auteur
Documents disponibles écrits par cet auteur (14)
Ajouter le résultat dans votre panier Faire une suggestion Affiner la recherche
Article : Périodique
C. HINDOCHA ; N. D. C. SHABAN ; T. P. FREEMAN ; R. K. DAS ; G. GALE ; G. SCHAFER ; C. J. FALCONER ; C. J. A. MORGAN ; H. V. CURRAN |Aims: To determine the degree to which cigarette smoking predicts levels of cannabis dependence above and beyond cannabis use itself, concurrently and in an exploratory four-year follow-up, and to investigate whether cigarette smoking mediates t[...]
Article : Périodique
T. P. FREEMAN ; S. CRAFT ; J. WILSON ; S. STYLIANOU ; M. ELSOHLY ; M. DI FORTI ; M. T. LYNSKEY |BACKGROUND AND AIMS: Cannabis products with high delta-9-tetrahydrocannabinol (THC) concentrations carry an increased risk of addiction and mental health disorders, while it has been suggested that cannabidiol (CBD) may moderate the effects of T[...]
Article : Périodique
K. R. THOMSEN ; C. LINDHOLST ; B. THYLSTRUP ; S. KVAMME ; L. A. REITZEL ; M. WORM-LEONHARD ; A. ENGLUND ; T. P. FREEMAN ; M. HESSE |Globally, recent studies report increases in Delta-9-tetrahydrocannabinol (THC) concentration in seized samples of cannabis for human consumption. This is important, because use of cannabis with a high concentration of THC has been linked to a n[...]
Article : Périodique
Aims - Use of the stimulant drug mephedrone increased dramatically in 2009, and it is still available in the United Kingdom after being controlled in April 2010. This study aimed to assess mephedrone's acute cognitive and subjective effects. De[...]Article : Périodique
B. HUGHES, Auteur ; A. R. WINSTOCK, Auteur ; K. KRAJEWSKI, Auteur du commentaire ; J. SHERIDAN, Auteur du commentaire ; B. ATMORE, Auteur du commentaire ; B. RUSSELL, Auteur du commentaire ; P. REUTER, Auteur du commentaire ; T. P. FREEMAN, Auteur du commentaire ; H. V. CURRAN, Auteur du commentaire |Aims: The rapid emergence of myriad substances openly marketed as ‘legal highs’ is straining traditional drug control systems which require time and basic scientific data on harms to react, presenting governments with the dilemma of no response [...]
Article : Périodique
M. GRABSKI ; J. WALDRON ; T. P. FREEMAN ; C. MOKRYSZ ; R. J. J. VAN BEEK ; P. VAN DER POL ; B. HAUSPIE ; N. DIRKX ; J. SCHROOTEN ; T. H. ELGAN ; K. FELTMAN ; E. BENEDETTI ; G. SCALIA TOMBA ; F. FABI ; S. MOLINARO ; J. GRIPENBERG ; T. VAN HAVERE ; M. VAN LAAR ; H. V. CURRAN |BACKGROUND: Monitoring emerging trends in the increasingly dynamic European drug market is vital; however, information on change at the individual level is scarce. In the current study, we investigated changes in drug use over 12 months in Europ[...]
Article : Périodique
Background. Cannabis use is decreasing in England and Wales, while demand for cannabis treatment in addiction services continues to rise. This could be partly due to an increased availability of high-potency cannabis. Method. Adults residing in[...]Article : Périodique
ENGLISH: AIMS: To quantify changes in (i) potency (concentration of Delta9-tetrahydrocannabinol; %THC), (ii) price (euros/g of cannabis) and (iii) value (mg THC/euro) of cannabis resin and herbal cannabis in Europe. DESIGN: Repeated cross-sect[...]
Article : Périodique
What you need to know: Cannabis based products for medicinal use contain cannabinoids derived from the cannabis plant, including Delta9-tetrahydrocananbinol (THC), cannabidiol (CBD), or a combination of THC and CBD. Synthetic cannabinoids for m[...]
Article : Périodique
ENGLISH: Through the potency monitoring program at the University of Mississippi supported by National Institute on Drug Abuse (NIDA), a total of 18108 samples of cannabis preparations have been analyzed over the last decade, using a validated [...]Article : Périodique
BACKGROUND AND AIMS: Cannabis products are becoming increasingly diverse, and vary considerably in concentrations of Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Higher doses of THC can increase the risk of harm from cannabis, while [...]
Article : Périodique
M. DI FORTI ; D. QUATTRONE ; T. P. FREEMAN ; G. TRIPOLI ; C. GAYER-ANDERSON ; H. QUIGLEY ; V. RODRIGUEZ ; H. E. JONGSMA ; L. FERRARO ; C. LA CASCIA ; D. LA BARBERA ; I. TARRICONE ; D. BERARDI ; A. SZOKE ; C. ARANGO ; A. TORTELLI ; E. VELTHORST ; M. BERNARDO ; C. M. DEL-BEN ; P. R. MENEZES ; J. P. SELTEN ; P. B. JONES ; J. B. KIRKBRIDE ; B. P. F. RUTTEN ; L. DE HAAN ; P. C. SHAM ; J. VAN OS ; C. M. LEWIS ; M. LYNSKEY ; C. MORGAN ; R. M. MURRAY ; EU-GEI WP2 Group |Background: Cannabis use is associated with increased risk of later psychotic disorder but whether it affects incidence of the disorder remains unclear. We aimed to identify patterns of cannabis use with the strongest effect on odds of psychotic[...]Article : Périodique
V. LORENZETTI ; C. HINDOCHA ; K. PETRILLI ; P. GRIFFITHS ; J. BROWN ; A. CASTILLO-CARNIGLIA ; J. P. CAULKINS ; A. ENGLUND ; M. A. ElSOHLY ; S. H. GAGE ; T. GROSHKOVA ; A. GUAL ; D. HAMMOND ; W. LAWN ; H. LOPEZ-PELAYO ; J. MANTHEY ; C. MOKRYSZ ; R. L. PACULA ; M. VAN LAAR ; R. VANDREY ; E. WADSWORTH ; A. WINSTOCK ; W. HALL ; H. V. CURRAN ; T. P. FREEMAN |BACKGROUND: The lack of an agreed international minimum approach to measuring cannabis use hinders the integration of multidisciplinary evidence on the psychosocial, neurocognitive, clinical and public health consequences of cannabis use. METH[...]Article : Périodique
J. WILSON ; K. MILLS ; T. P. FREEMAN ; M. SUNDERLAND ; R. VISONTAY ; C. MAREL |BACKGROUND AND AIMS: The idea that cannabis is a 'gateway drug' to more harmful substances such as opioids is highly controversial, yet has substantially impacted policy, education and how we conceptualize substance use. Given a rise in access t[...]
